Ali Rashidfarrokhi

Ali Rashidfarrokhi

Auto-generated profile, based on publicly available information

Ali Rashidfarrokhi

Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2026 in Science
Verified
Journal Article
Closed access
MCMichael Cross
Michael Cross
SKStefan Kotschi
Stefan Kotschi
WWWarren Wu
Warren Wu
FLFedra Luciano-Mateo
Fedra Luciano-Mateo
YKYoung-Yon Kwon
Young-Yon Kwon
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
Sickness behaviors are common in cancer-associated cachexia and affect up to half of lung cancer patients. We demonstrate that among the most common cancer mutations, loss of liver kinase B1 ( Lkb1 ) promotes the development of cachexia in preclinical models of lung cancer. In an effort to improve caloric intake with an obesogenic high-fat diet, we paradoxically observed worsened cachexia-associated sickness. We found that local production of prostaglandin E2 (PGE 2 ), rather than circulating factors, promotes sickness and that genetic, dietary, and pharmacological inhibition of tumor-derived PGE 2 suppresses sickness and cachexia. Notably, we demonstrate that lung sensory neuron abrogation prevents PGE 2 -dependent cachexia. Our study establishes localized tumor-derived signals to sensory neurons, rather than circulating factors, as drivers of cachexia and highlights a previously unknown role of the peripheral nervous system in cancer cachexia.

17 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ARAli Rashidfarrokhi
Ali Rashidfarrokhi
RPRay Pillai
Ray Pillai
YHYuan Hao
Yuan Hao
WWWarren L. Wu
Warren L. Wu
BKBurcu Karadal-Ferrena
Burcu Karadal-Ferrena
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
SUMMARY: Tumor mutations can influence the surrounding microenvironment leading to suppression of anti-tumor immune responses and thereby contributing to tumor progression and failure of cancer therapies. Here we use genetically engineered lung cancer mouse models and patient samples to dissect how LKB1 mutations accelerate tumor growth by reshaping the immune microenvironment. Comprehensive immune profiling of LKB1 -mutant vs wildtype tumors revealed dramatic changes in myeloid cells, specifically enrichment of Arg1 + interstitial macrophages and SiglecF Hi neutrophils. We discovered a novel mechanism whereby autocrine LIF signaling in Lkb1 -mutant tumors drives tumorigenesis by reprogramming myeloid cells in the immune microenvironment. Inhibiting LIF signaling in Lkb1 -mutant tumors, via gene targeting or with a neutralizing antibody, resulted in a striking reduction in Arg1 + interstitial macrophages and SiglecF Hi neutrophils, expansion of antigen specific T cells, and inhibition of tumor progression. Thus, targeting LIF signaling provides a new therapeutic approach to reverse the immunosuppressive microenvironment of LKB1 -mutant tumors.

20 April 2026 in Cancer Discovery
Verified
Journal Article
Open access
RPRay Pillai
Ray Pillai
ARAli Rashidfarrokhi
Ali Rashidfarrokhi
YHYuan Hao
Yuan Hao
WWWarren L. Wu
Warren L. Wu
MMMariana C.S. Mancini
Mariana C.S. Mancini
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
LKB1 mutations in lung cancer promote an immunosuppressive tumor microenvironment, but the underlying mechanisms remain unknown. Using genetically engineered mouse models and human tumor samples, we demonstrate that LKB1 loss leads to high expression of the cytokine leukemia-inhibitory factor (LIF), which through a cancer cell–autonomous autocrine loop, orchestrates the infiltration of immunosuppressive SiglecFHi neutrophils and Arg1+ interstitial macrophages. Genetic deletion of Lifr, the receptor for LIF, on Lkb1-mutant lung tumors revealed that autocrine LIF signaling induces tumor plasticity and the emergence of a Sox17+ dedifferentiated inflammatory cell state. Antibody-mediated LIF neutralization selectively eliminates the Sox17+ tumor cell state, reduces immunosuppressive myeloid cells, and enhances antitumor T-cell responses. Our study uncovers a novel LKB1–LIF axis driving immune evasion and identifies LIF as a potential therapeutic target in LKB1-mutant lung cancer. This work highlights the interplay between tumor genetics, cellular plasticity, and immune regulation in lung cancer progression. Significance: LKB1-mutant lung cancers express LIF, which induces an immunosuppressive Sox17+ tumor state. Anti-LIF therapy eliminates this state and restores antitumor immunity, revealing a novel vulnerability in this aggressive cancer subtype lacking effective targeted therapies.

1 July 2026
Verified
Other
Open access
RPRay Pillai
Ray Pillai
ARAli Rashidfarrokhi
Ali Rashidfarrokhi
YHYuan Hao
Yuan Hao
WWWarren L. Wu
Warren L. Wu
MMMariana C.S. Mancini
Mariana C.S. Mancini
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
Inhibition of autocrine LIF signaling enhances T cell effector function.


1 July 2026
Verified
Other
Open access
PDF file
RPRay Pillai
Ray Pillai
ARAli Rashidfarrokhi
Ali Rashidfarrokhi
YHYuan Hao
Yuan Hao
WWWarren L. Wu
Warren L. Wu
MMMariana C.S. Mancini
Mariana C.S. Mancini
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
Loss of function mutations in Lkb1 enhance tumorigenesis.